Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Unipharma Co's operating assets for the quarter that ended in Dec. 2025 was NT$139.64 Mil. Unipharma Co's operating liabilities for the quarter that ended in Dec. 2025 was NT$34.22 Mil. Unipharma Co's Total Assets for the quarter that ended in Jun. 2025 was NT$291.61 Mil. Therefore, Unipharma Co's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.36.
Unipharma Co Scaled Net Operating Assets Related Terms
Unipharma Co Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Unipharma Co's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6621 vs ZTS, UTHR: Scaled Net Operating Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unipharma Co Scaled Net Operating Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Unipharma Co's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.36 mean?
Unipharma Co (ROCO:6621) has a Scaled Net Operating Assets of 0.36 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Unipharma Co and its competitors.
Is Unipharma Co's Scaled Net Operating Assets too high?
Unipharma Co's current Scaled Net Operating Assets is 0.36. Overall, Unipharma Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unipharma Co's Scaled Net Operating Assets compare to ZTS and UTHR?
Unipharma Co's Scaled Net Operating Assets of 0.36 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Unipharma Co and its competitors. Unipharma Co's current Scaled Net Operating Assets is 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unipharma Co stock overvalued right now?
Based on GuruFocus' analysis, Unipharma Co (ROCO:6621) is currently considered Fairly Valued. The stock's GF Value™ is NT$11.58, compared to a current price of NT$11.30 — trading 2.4% below its estimated fair value. The current Scaled Net Operating Assets is 0.36. Unipharma Co's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Unipharma Co (ROCO:6621), the current Scaled Net Operating Assets is 0.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unipharma Co (ROCO:6621) Overvalued in 2026?
Based on GuruFocus' analysis, Unipharma Co stock appears to be undervalued.
The current stock price of NT$11.30 is trading 2.4% below its estimated GF Value™ of NT$11.58.
GuruFocus considers Unipharma Co to be Fairly Valued.
Key valuation signals for ROCO:6621:
Scaled Net Operating Assets: 0.36
GF Value™: NT$11.58 vs. price of NT$11.30 (2.4% below fair value)
No single metric tells the full story. See the ROCO:6621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.
74GF Score
Get the complete analysis for ROCO:6621
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6621 has been successfully added to your 
